As IVF become increasingly automated, it seems inevitable that it will follow the cost curve of most technology-intensive processes and get cheaper.
About one in six couples of reproductive age suffer from infertility, but as the industry becomes more tech focused, IVF will become cheaper. This will put it within reach for thousands of couples who are currently unable to afford it.
CSL looks like being the best positioned to take advantage of the next period of undersupply of blood plasma. So what does it mean for investors?
The success of Ansell, the glove and condom maker, depends on two competitive advantages. We look at what they are, and why they matter.